Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
10:23am, Wednesday, 24'th Sep 2025
uniQure N.V. QURE on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington's disease.
UniQure's brain disorder drug slows disease progression in trial
07:28am, Wednesday, 24'th Sep 2025
UniQure's experimental gene therapy significantly slowed the progression of a brain disorder in an early-to-mid stage study, it said on Wednesday.
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
07:10am, Wednesday, 24'th Sep 2025
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 millio
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
07:05am, Wednesday, 24'th Sep 2025
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external co
uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data
04:57pm, Friday, 05'th Sep 2025
uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash rese
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet
10:56am, Thursday, 31'st Jul 2025
The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
09:07pm, Tuesday, 29'th Jul 2025
uniQure N.V. (NASDAQ:QURE ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Ab
uniQure Narrows Loss in Fiscal Q2
09:34am, Tuesday, 29'th Jul 2025
uniQure Narrows Loss in Fiscal Q2
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
09:16am, Tuesday, 29'th Jul 2025
uniQure (QURE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $1.16 per share a year ago.
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
07:05am, Tuesday, 29'th Jul 2025
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
uniQure to Announce Second Quarter 2025 Financial Results
07:05am, Tuesday, 22'nd Jul 2025
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
08:00am, Wednesday, 11'th Jun 2025
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
07:05am, Monday, 02'nd Jun 2025
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
04:56am, Wednesday, 28'th May 2025
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough T
